Physicians' Academy for Cardiovascular Education

Which patients to consider for GLP-1RA?

5 Things a cardiologist needs to know about GLP-1RA

*NEW* Click on video for subtitling in English, German, Italian, Spanish, French, or Chinese.

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Villingen-Schwenningen, Germany

Video navigation menu

  • Case presentation - Should we modify the glucose lowering medication? 00:23
  • What would the guidelines recommend? 02:19
  • Evolution of treatment recommendations in management of T2DM 04:22
  • Use of anti-glycemic drugs with CV benefit in reality 05:41
  • Who should modify the risk management - a Cardiometabolic specialist? 06:42

Transcript

Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1 RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.

Faculty

Prof Stephan Jacob, MD - endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany.

Disclosures

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Or listen to the podcast of this presentation

Share this page with your colleagues and friends: